Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
- Medical care costs associated with cancer survivorship in the United States.Cancer Epidemiol Biomarkers Prev. 2020; 29: 1304-1312
- Employer health benefits chart pack.(Available at:)https://www.kff.org/slideshow/2020-employer-health-benefits-chart-pack/Date: 2020Date accessed: October 13, 2020
- Death or debt? National estimates of financial toxicity in persons with newly-diagnosed cancer.Am J Med. 2018; 131: 1187-1199.e5
- The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience.Oncologist. 2013; 18: 381-390
- Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.Gynecol Oncol. 2020; 156: 271-277
- Financial toxicity in gynecologic oncology.Gynecol Oncol. 2019; 154: 8-12
- A systematic review of financial toxicity among cancer survivors: we can’t pay the co-pay.Patient. 2017; 10: 295-309
- Increases in cost-sharing payments continue to outpace wage growth. Health System Tracker.(Available at:)https://www.healthsystemtracker.org/brief/increases-in-cost-sharing-payments-have-far-outpaced-wage-growth/Date: 2018Date accessed: October 10, 2020
- Social needs in gynecologic oncology: a Society of Gynecologic Oncology (SGO) clinical practice statement.Gynecol Oncol. 2020; 158: 521-525
- Financial insolvency as a risk factor for early mortality among patients with cancer.J Clin Oncol. 2016; 34: 980-986
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.Lancet. 2010; 376: 1155-1163
- Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer.JAMA Oncol. 2016; 2: 1427-1433
- Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents.J Clin Oncol. 2018; 36: 476-482
- Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies.J Surg Oncol. 2019; 120: 85-92
- American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options.J Clin Oncol. 2015; 33: 2563-2577
E.M.A. and B.L.M.G. are cofirst authors.
Outside the submitted work, M.M.L. Jr reports personal fees from Johnson & Johnson and Ethicon, Takeda, and Intuitive Surgical , Inc. Furthermore, he reports institutional research funding from Kinetic Concepts/Acelity. N.R.A.R reports grants from Stryker/Novadaq and GRAIL. D.S.C. reports personal fees from Bovie Medical Corporation; Verthermia, Inc (now Apyx Medical Corporation); Biom'Up, and CSurgeries and other grants from Intuitive Surgical, Inc; Doximity, and TransEnterix, Inc. E.L.J reports personal fees from Covidien/Medtronic. The remaining authors report no conflict of interest.
This study was funded, in part, through the National Institutes of Health /National Cancer Institute Cancer Center Support Grant P30 CA008748.
Cite this article as: Aviki EM, Manning-Geist BL, Sokolowski SS, et al. Risk factors for financial toxicity in patients with gynecologic cancer. Am J Obstet Gynecol 2022;226:817.e1-9.